Physician profile
Baha Eddin El Khatib
NPI 1417481946
$14,708.98
in general payments reported to CMS, 2019-2025
14 companies · $13K in 2025
The $13K reported for 2025 was more than what 92% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2023: $98.00 · 2024: $1,338 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $3,008 · Travel and Lodging: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,340.00 |
| Food and Beverage | $3,008.38 |
| Travel and Lodging | $959.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $11,588.63 | 2024-2025 | Eylea Hd |
| Regeneron Healthcare Solutions, INC. | $610.08 | 2024-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $503.45 | 2023-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $478.94 | 2024-2025 | Syfovre |
| Alcon Vision LLC | $401.10 | 2021 | |
| Astellas Pharma US INC | $238.97 | 2024-2025 | Izervay |
| Genentech USA, INC. | $203.65 | 2024-2025 | Vabysmo, Susvimo |
| Ocular Therapeutix, INC. | $152.17 | 2024 | Dextenza |
| Abbvie INC. | $146.86 | 2024-2025 | |
| Astellas Pharma Global Development | $143.46 | 2025 | Izervay |
| Harrow Eye, LLC | $125.03 | 2024-2025 | Iheezo, Triesence |
| Ani Pharmaceuticals, INC. | $60.74 | 2025 | Iluvien, Yutiq |
| Rayner Intraocular Lenses Limited | $37.94 | 2024 | Rayner Cataract Set 1, Rayone Aspheric, Rayone Emv |
| Bausch & Lomb Americas INC. | $17.96 | 2025 | Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baha Eddin El Khatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.